Mauna Kea Technologies

Equities

ALMKT

FR0010609263

Advanced Medical Equipment & Technology

Real-time Euronext Paris 14:31:03 14/06/2024 BST 5-day change 1st Jan Change
0.3835 EUR -3.40% Intraday chart for Mauna Kea Technologies -11.02% -18.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Mauna Kea: favorable data in pancreatic cysts CF
Mauna Kea obtains operating license in China CF
Mauna Kea Technologies Announces Joint Venture in China Obtains Class II Medical Device Business License CI
Mauna Kea Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mauna Kea Technologies SA Announces the Opening of A French Center of Excellence for the Use of Cellvizio in Lung Cancer Diagnostics CI
Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024 CI
Mauna Kea: first Italian center for Cellvizio CF
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio CI
Mauna Kea: partnership with Metrodora Institute in the USA CF
Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults CI
Mauna Kea: Johnson & Johnson Innovation below 20% threshold CF
Mauna Kea Technologies to Receive EUR6 Million Investment from Telix Pharmaceuticals MT
Mauna Kea: share price surges as Telix acquires 19% stake CF
Telix Pharmaceuticals Limited and Mauna Kea Technologies SA to Expand Collaboration in Urologic Oncology Surgery CI
Mauna Kea Technologies SA announced that it expects to receive ?6 million in funding from Telix Pharmaceuticals Limited CI
Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer CI
Mauna Kea Technologies Reports Sales Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Mauna Kea: positive results in pneumology boost share price CF
Mauna Kea Technologies SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Mauna Kea: 1200 Cellvizio procedures completed at EIH CF
Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone CI
Mauna Kea: transfer to Euronext Growth on August 8 CF
Mauna Kea Technologies to Transfer Shares to Euronext Growth Paris MT
Transcript : Mauna Kea Technologies SA, H1 2023 Sales/ Trading Statement Call, Jul 20, 2023
Mauna Kea: Cellvizio platform installed in Ireland CF
Chart Mauna Kea Technologies
More charts
Mauna Kea Technologies specializes in designing, developing, and selling optical biopsy devices and tools. The group's products are intended for visualizing and detecting cellular abnormalities during the gastrointestinal and pulmonary endoscopic procedures, primarily in cancer patients. Net sales break down by activity as follows: - sale of licenses (40.7%); - sales of accessories (37.3%): mini-probes, software, etc.; - sales of system (11.2%); - services (10.8%). Net sales are distributed geographically as follows: Europe/Middle East/Africa (15.5%), the United States and Canada (42.9%) and Asia (41.6%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.397 EUR
Average target price
2 EUR
Spread / Average Target
+403.78%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. ALMKT Stock
  4. News Mauna Kea Technologies
  5. Mauna Kea Technologies to Transfer Shares to Euronext Growth Paris
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW